VTVT
vTv Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$33.35
−0.36%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +73.2%
- EBIT
- +63.9%
- EPS
- +96.6%
- Free cash flow
- +23.9%
- Operating cash flow
- +23.9%
Forward estimates
Based on analyst estimates
- Revenue
- -99.1%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -37.9%
- EBIT
- -35.7%
- Net income
- -46.1%
- EPS
- +0.0%
- Free cash flow
- +0.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026